NLTX logo

Neoleukin Therapeutics (NLTX) Cash From Operations

Annual CFO

-$45.61 M
+$1.95 M+4.10%

December 31, 2022

Summary

Performance

1-Year Change

+4.1%

3-Year Change

-196.26%

5-Year Change

-1.99%

15-Year Change

-1.99%

NLTX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$7.23 M

3-Year Low

-$47.56 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
NLTX previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
NLTX next annual earnings announcement has not yet been scheduled

OtherNLTXcash flowmetrics:

Annual CFI

-$59.13 M
NLTX annual cash flow from investing activities is -$59.13 million

Annual CFF

$161.00 K
NLTX annual cash flow from financing activities is $161.00 thousand

Annual FCF

-$46.72 M
NLTX annual free cash flow is -$46.72 million

Annual CAPEX

-
NLTX annual capital expenditures value is unknown

Quarterly CFO

-$4.27 M
-$220.00 K-5.43%

September 30, 2023

Summary

Performance

3-Month Change

-5.43%

1-Year Change

+54.04%

3-Year Change

-3711.61%

5-Year Change

+72.27%

NLTX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$9.18 M
NLTX quarterly cash flow from operations is currently -146.50% below its historical high of $9.18 million

3-Year Low

-$14.09 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
NLTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
NLTX next earnings announcement has not yet been scheduled

OtherNLTXcash flowmetrics:

Quarterly CFI

-$1.61 M
NLTX quarterly cash flow from investing activities is -$1.61 million

Quarterly CFF

-$1000.00
NLTX quarterly cash flow from financing activities is -$1000.00

Quarterly FCF

-$4.27 M
NLTX quarterly free cash flow is -$4.27 million

Quarterly CAPEX

-
NLTX quarterly capital expenditures value is unknown

TTM CFO

-$32.28 M
+$5.02 M+13.46%

September 30, 2023

Summary

Performance

3-Month Change

+13.46%

1-Year Change

+31.08%

3-Year Change

-61.57%

5-Year Change

-109.72%

NLTX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$896.60 K

3-Year Low

-$48.29 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
NLTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
NLTX next earnings announcement has not yet been scheduled

OtherNLTXcash flowmetrics:

TTM CFI

$17.15 M
NLTX TTM cash flow from investing activities is $17.15 million

TTM CFF

-$343.00 K
NLTX TTM cash flow from financing activities is -$343.00 thousand

TTM FCF

-$32.94 M
NLTX TTM free cash flow is -$32.94 million

TTM CAPEX

-
NLTX TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

NLTX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+4.1%+54.0%+31.1%
3 y3 years-196.3%-3711.6%-61.6%
5 y5 years-2.0%+72.3%-109.7%

NLTX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+4.3%+5.4%+230.1%at high+49.6%
5 y5-year+196.3%+4.3%+3711.6%+230.1%+109.7%+49.6%
alltimeall time+530.6%+4.3%-146.5%+265.2%+3500.7%+51.9%

Neoleukin Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2023
-
-$4.27 M(+5.4%)
-$32.28 M(-13.5%)
Jun 2023
-
-$4.05 M(-68.9%)
-$37.30 M(-16.3%)
Mar 2023
-
-$13.03 M(+19.2%)
-$44.55 M(-2.3%)
Dec 2022
-$45.61 M(-4.1%)
-$10.93 M(+17.7%)
-$45.61 M(-2.6%)
Sep 2022
-
-$9.29 M(-17.8%)
-$46.84 M(+1.2%)
Jun 2022
-
-$11.29 M(-19.8%)
-$46.31 M(-4.1%)
Mar 2022
-
-$14.09 M(+15.8%)
-$48.29 M(+1.5%)
Dec 2021
-$47.56 M(+93.5%)
-$12.17 M(+39.0%)
-$47.56 M(+6.6%)
Sep 2021
-
-$8.76 M(-34.0%)
-$44.62 M(+24.0%)
Jun 2021
-
-$13.28 M(-0.6%)
-$35.98 M(+14.2%)
Mar 2021
-
-$13.36 M(+44.7%)
-$31.49 M(+28.2%)
Dec 2020
-$24.57 M(+59.6%)
-$9.23 M(+8140.2%)
-$24.57 M(+23.0%)
Sep 2020
-
-$112.00 K(-98.7%)
-$19.98 M(-24.3%)
Jun 2020
-
-$8.79 M(+36.6%)
-$26.40 M(+38.4%)
Mar 2020
-
-$6.44 M(+38.9%)
-$19.08 M(+23.9%)
Dec 2019
-$15.39 M(-51.2%)
-$4.64 M(-29.0%)
-$15.39 M(-25.0%)
Sep 2019
-
-$6.53 M(+344.4%)
-$20.53 M(-30.1%)
Jun 2019
-
-$1.47 M(-46.7%)
-$29.39 M(+56.8%)
Mar 2019
-
-$2.76 M(-71.8%)
-$18.74 M(-40.6%)
Dec 2018
-$31.58 M
-$9.78 M(-36.5%)
-$31.58 M(-5.5%)
Sep 2018
-
-$15.39 M(-267.7%)
-$33.41 M(+13.1%)
Jun 2018
-
$9.18 M(-158.9%)
-$29.54 M(-39.7%)
DateAnnualQuarterlyTTM
Mar 2018
-
-$15.59 M(+34.3%)
-$49.03 M(+9.6%)
Dec 2017
-$44.72 M(+47.9%)
-$11.61 M(+0.7%)
-$44.72 M(+6.2%)
Sep 2017
-
-$11.53 M(+11.9%)
-$42.11 M(+10.8%)
Jun 2017
-
-$10.30 M(-8.7%)
-$38.02 M(+6.7%)
Mar 2017
-
-$11.28 M(+25.4%)
-$35.63 M(+17.9%)
Dec 2016
-$30.23 M(+49.1%)
-$9.00 M(+20.9%)
-$30.23 M(+20.0%)
Sep 2016
-
-$7.44 M(-6.0%)
-$25.19 M(+12.7%)
Jun 2016
-
-$7.92 M(+34.8%)
-$22.36 M(+12.7%)
Mar 2016
-
-$5.87 M(+48.4%)
-$19.84 M(-2.1%)
Dec 2015
-$20.27 M(+15.9%)
-$3.96 M(-14.2%)
-$20.27 M(-11.9%)
Sep 2015
-
-$4.61 M(-14.6%)
-$23.00 M(+1.9%)
Jun 2015
-
-$5.40 M(-14.3%)
-$22.58 M(+13.0%)
Mar 2015
-
-$6.30 M(-5.9%)
-$19.98 M(+14.3%)
Dec 2014
-$17.49 M(+123.5%)
-$6.69 M(+60.0%)
-$17.49 M(+20.3%)
Sep 2014
-
-$4.18 M(+49.1%)
-$14.53 M(+20.2%)
Jun 2014
-
-$2.81 M(-26.2%)
-$12.09 M(+12.7%)
Mar 2014
-
-$3.80 M(+1.7%)
-$10.73 M(+37.2%)
Dec 2013
-$7.82 M(+8.2%)
-$3.74 M(+114.3%)
-$7.82 M(+91.6%)
Sep 2013
-
-$1.74 M(+21.0%)
-$4.08 M(+74.6%)
Jun 2013
-
-$1.44 M(+60.8%)
-$2.34 M(+160.8%)
Mar 2013
-
-$896.60 K
-$896.60 K
Dec 2012
-$7.23 M
-
-

FAQ

  • What is Neoleukin Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics annual CFO year-on-year change?
  • What is Neoleukin Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics quarterly CFO year-on-year change?
  • What is Neoleukin Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics TTM CFO year-on-year change?

What is Neoleukin Therapeutics annual cash flow from operations?

The current annual CFO of NLTX is -$45.61 M

What is the all time high annual CFO for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high annual cash flow from operations is -$7.23 M

What is Neoleukin Therapeutics annual CFO year-on-year change?

Over the past year, NLTX annual cash flow from operations has changed by +$1.95 M (+4.10%)

What is Neoleukin Therapeutics quarterly cash flow from operations?

The current quarterly CFO of NLTX is -$4.27 M

What is the all time high quarterly CFO for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high quarterly cash flow from operations is $9.18 M

What is Neoleukin Therapeutics quarterly CFO year-on-year change?

Over the past year, NLTX quarterly cash flow from operations has changed by +$5.02 M (+54.04%)

What is Neoleukin Therapeutics TTM cash flow from operations?

The current TTM CFO of NLTX is -$32.28 M

What is the all time high TTM CFO for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high TTM cash flow from operations is -$896.60 K

What is Neoleukin Therapeutics TTM CFO year-on-year change?

Over the past year, NLTX TTM cash flow from operations has changed by +$14.56 M (+31.08%)